Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus MOR00208 in relapsed or refractory diffuse large B-cell lymphoma
2014-004688-19Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Jul 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by MorphoSys AG. Primary endpoint: Overall Response Rate. Started Jul 2015; status: completed.
02
Drugs
lenalidomidetafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2014-004688-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004688-19.